Guru Ownership Trend
Guru Analysis for Enanta Pharmaceuticals, Inc. (ENTA)
Enanta Pharmaceuticals, Inc. (ENTA), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $13.19 M.
Top institutional holders include Renaissance Technologies (RenTech) and Cliff Asness.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $5.51 M net outflow during the quarter.
Recent activity highlights Paul Tudor Jones who opened a new position.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Enanta Pharmaceuticals, Inc. (ENTA)
Major holders include Renaissance Technologies (RenTech) ($8.4 M), Cliff Asness ($3.96 M), Paul Tudor Jones ($131,112). According to the latest reported data, 3 tracked investment managers collectively hold approximately 988,796 shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $5.51 M, with 3 managers increasing positions and 1 managers reducing holdings.
During the most recent reporting period, 0 managers trimmed their positions, while 1 fully exited ENTA. The total reported sell value was $6.92 M.
Yes, 1 managers opened new positions in ENTA, and 2 increased their existing holdings. The total reported buy value was $1.41 M.